These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37357077)

  • 1. Humoral and cellular immune responses in sheep following administration of different doses of an inactivated phase I vaccine against Coxiella burnetii.
    Bauer BU; Schwecht KM; Jahnke R; Matthiesen S; Ganter M; Knittler MR
    Vaccine; 2023 Jul; 41(33):4798-4807. PubMed ID: 37357077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response to Q fever vaccination of three sheep flocks naturally pre-infected with Coxiella burnetii.
    Bauer BU; Knittler MR; Prüfer TL; Wolf A; Matthiesen S; Runge M; Ganter M
    Vaccine; 2021 Mar; 39(10):1499-1507. PubMed ID: 33558108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term control of Coxiellosis in sheep by annual primary vaccination of gimmers.
    Böttcher J; Bauer BU; Ambros C; Alex M; Domes U; Roth S; Boll K; Korneli M; Bogner KH; Randt A; Janowetz B
    Vaccine; 2022 Aug; 40(35):5197-5206. PubMed ID: 35914960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a phase I Coxiella burnetii inactivated vaccine on body temperature and milk yield in dairy cows.
    Schulze LS; Borchardt S; Ouellet V; Heuwieser W
    J Dairy Sci; 2016 Jan; 99(1):541-50. PubMed ID: 26547657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of
    Bauer BU; Schoneberg C; Herms TL; Kleinschmidt S; Runge M; Ganter M
    Front Vet Sci; 2022; 9():1064763. PubMed ID: 36601330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience in vaccinating farm animals for preventing Q fever in humans].
    Lisák V
    Tr Inst Im Pastera; 1989; 66():143-53, 174. PubMed ID: 2485300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Efficacy of a Commercial Phase I Inactivated Vaccine in Decreasing the Prevalence of
    González-Barrio D; Ortiz JA; Ruiz-Fons F
    Front Vet Sci; 2017; 4():208. PubMed ID: 29270411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of phase I inactivated vaccines to reduce shedding of Coxiella burnetii from sheep and goats from routes of public health importance.
    O'Neill TJ; Sargeant JM; Poljak Z
    Zoonoses Public Health; 2014 Dec; 61(8):519-33. PubMed ID: 24251777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Phase I and Phase II
    Williams-Macdonald SE; Mitchell M; Frew D; Palarea-Albaladejo J; Ewing D; Golde WT; Longbottom D; Nisbet AJ; Livingstone M; Hamilton CM; Fitzgerald SF; Buus S; Bach E; Dinkla A; Roest HJ; Koets AP; McNeilly TN
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial of the immunogenicity and safety of a formaldehyde-inactivated Coxiella burnetii vaccine in 8-week-old goats.
    Muleme M; Devlin JM; Campbell A; Vincent G; Benham PJ; Sprohnle C; Stent A; Cameron A; Islam A; Graves S; Wilks C; Stenos J; Firestone SM
    Vet Immunol Immunopathol; 2021 Jun; 236():110253. PubMed ID: 33940537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QuilA® adjuvanted Coxevac® sustains Th1-CD8
    Tomaiuolo S; Jansen W; Soares Martins S; Devriendt B; Cox E; Mori M
    NPJ Vaccines; 2023 Feb; 8(1):17. PubMed ID: 36788233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coxiella burnetii DNA in goat milk after vaccination with Coxevac(®).
    Hermans MH; Huijsmans CR; Schellekens JJ; Savelkoul PH; Wever PC
    Vaccine; 2011 Mar; 29(15):2653-6. PubMed ID: 21320538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetti for the immunization of animals.
    Williams JC; Peacock MG; Waag DM; Kent G; England MJ; Nelson G; Stephenson EH
    Ann N Y Acad Sci; 1992 Jun; 653():88-111. PubMed ID: 1626897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Q fever in pregnant goats: humoral and cellular immune responses.
    Roest HI; Post J; van Gelderen B; van Zijderveld FG; Rebel JM
    Vet Res; 2013 Aug; 44(1):67. PubMed ID: 23915213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation and Haematological Profile of an Inactivated RVF Vaccine Locally Produced in Egypt.
    S Mousa W; A Aly M; A Zaghawa A; A Aita R; S Mohamed S; Faried Abdelaziz R; A Nayel M; M Elsify A; A Salama A
    Pak J Biol Sci; 2022 Jan; 25(6):476-484. PubMed ID: 36098182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii.
    Waag DM; England MJ; Bolt CR; Williams JC
    Clin Vaccine Immunol; 2008 Oct; 15(10):1505-12. PubMed ID: 18701647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of recombinant Ybgf protein for the detection of
    Ferrara G; Colitti B; Pagnini U; Iovane G; Rosati S; Montagnaro S
    J Vet Diagn Invest; 2022 Jul; 34(4):646-653. PubMed ID: 35610946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited humoral and cellular responses to Q fever vaccination in older adults with risk factors for chronic Q fever.
    Schoffelen T; Herremans T; Sprong T; Nabuurs-Franssen M; Wever PC; Joosten LA; Netea MG; van der Meer JW; Bijlmer HA; van Deuren M
    J Infect; 2013 Dec; 67(6):565-73. PubMed ID: 23973626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.